Preora Diagnostics Inc.
Noninvasive lung cancer detection
This article was originally published in Start Up
Executive Summary
Just as the PAP smear has drastically reduced the incidence and number of deaths from cervical cancer over the decades, Preora Diagnostics Inc. expects its low-cost test to be an effective prescreening tool for lung cancer, in the convenience of a primary-care setting. The start-up believes its test will be able to identify asymptomatic stage 1 and stage 2 cancers.
You may also be interested in...
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.